Abdul Mannan Inside the Diagnostic Maze of Atypical CML
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”It’s rare. It’s aggressive. It mimics other blood cancers.
No Philadelphia chromosome. No targeted therapy. Just tough decisions.
Diagnosis needs sharp eyes. Dysplastic cells. High white counts. Molecular clues.
SETBP1 and ASXL1 mutations tell the story.
CSF3R points elsewhere.
Median survival? 14-30 months without transplant.
But here’s hope: Early recognition matters. Molecular testing guides us. Transplant can cure selected patients.
Every rare diagnosis teaches us something profound about blood biology.
As haematologists, we don’t just treat diseases. We solve puzzles that save lives.
What rare condition taught you the most?”
Keep up with Hemostasis Today.
-
Sep 15, 2026, 11:17Adam Urato: How SSRIs May Affect Maternal and Fetal Serotonin
-
Sep 15, 2026, 11:05Sudhir Kumar: Maternal Anemia May Shape a Child’s Brain Development
-
Sep 15, 2026, 10:48Ashok Singhal: A Life-Changing Transplant Brings New Hope for Beta Thalassemia
-
Sep 15, 2026, 10:33Vera Ghali: Mitapivat Opens a New Chapter in Thalassemia Treatment
-
Sep 15, 2026, 10:13Behnood Bikdeli: Exploring the Role of Antiphospholipid Antibodies in Ischemic Stroke
-
Sep 15, 2026, 09:55Mark Mamlouk: When Postpartum Headache Signals More Than a CSF Leak
-
Sep 15, 2026, 09:46Nicholas Raccagni: Heparin for VTE Prevention After Traumatic Brain Injury
-
Sep 15, 2026, 09:34Mario D. Caldararo: Are Lines of Zahn Pathognomonic for Antemortem Thrombosis?
-
Sep 15, 2026, 09:24Vishakha K. Kumar: ISTH Is Hiring – Exhibition and Sponsorship Operations Manager